{"id":24025,"date":"2025-02-12T13:14:14","date_gmt":"2025-02-12T07:44:14","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=24025"},"modified":"2025-02-12T13:40:16","modified_gmt":"2025-02-12T08:10:16","slug":"leqembi-for-alzheimers-disease-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment","title":{"rendered":"LEQEMBI: A New Hope for Alzheimer\u2019s Disease Patients"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a10989f362a7\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a10989f362a7\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment\/#FDA_Approval_of_Leqembi_Major_Milestone_in_Alzheimers_Disease_Treatment_Space\" >FDA Approval of Leqembi: Major Milestone in Alzheimer\u2019s Disease Treatment Space<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment\/#Recent_Developments_Since_the_Approval\" >Recent Developments Since the Approval<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment\/#Promising_Candidates_in_the_Pipeline_for_Alzheimers_Disease_Treatment\" >Promising Candidates in the Pipeline for Alzheimer\u2019s Disease Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment\/#Promising_Future_Outlook_of_Alzheimers_Disease_Treatment\" >Promising Future Outlook of Alzheimer\u2019s Disease Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong>Alzheimer\u2019s disease<\/strong> is the most common type of dementia, accounting for more than <strong>60%<\/strong> of all cases, and is characterized by a gradual decline in cognitive and functional abilities. It represents a global health crisis that is increasing with the increasing geriatric population. It represents a global health crisis that is increasing with the increasing geriatric population.&nbsp;<\/p>\n\n\n\n<p>According to various studies among patients aged &gt;65 years, Alzheimer&#8217;s disease was the fifth leading cause of death. According to the<strong> World Health Organization (WHO), <\/strong>approximately <strong>50 million<\/strong> people worldwide have dementia. In the United States, it is estimated that more than <strong>6 million<\/strong> people have Alzheimer\u2019s disease. Alzheimer\u2019s disease is the sixth leading cause of death in the United States. As the global population ages, the prevalence of Alzheimer\u2019s disease is expected to rise significantly. By 2050, it is projected that the number of people with dementia worldwide will reach <strong>152 million.<\/strong><\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em><em>As per DelveInsight analysis, the <\/em><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-epidemiology-forecast\"><em>total diagnosed prevalent cases of Alzheimer\u2019s disease<\/em><\/a><em> in the 7MM were found to be approximately <strong>16 million cases in 2023, <\/strong>which are expected to increase by <strong>2034 <\/strong>at a <strong>significant CAGR<\/strong> during the<strong> study period (2020\u25002034)<\/strong>. The US accounted for nearly <strong>44%<\/strong> of the total diagnosed prevalent cases of Alzheimer\u2019s disease in the 7MM in the year 2023, which are expected to increase further by 2034.<\/em><\/em><\/p>\n\n\n\n<p>Many of the drugs currently available to treat dementia symptoms work by increasing the activity levels of some brain neurotransmitters, such as acetylcholine, serotonin, and noradrenaline, or decreasing the activity of others, such as glutamate and dopamine. It is also prohibited due to the accompanying negative effects. It is critical to personalize dementia symptomatic medicines by taking into account individuals\u2019 comorbidities and their associated therapies. The effects on cardiac function, medication elimination, and other interactions should be evaluated on a case-by-case basis.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"394\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12122806\/Alzheimers-Disease-Epidemiology-Insights-2023-1024x394.png\" alt=\"Alzheimer's-Disease-Epidemiology-Insights-(2023)\" class=\"wp-image-31001\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12122806\/Alzheimers-Disease-Epidemiology-Insights-2023-1024x394.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12122806\/Alzheimers-Disease-Epidemiology-Insights-2023-300x115.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12122806\/Alzheimers-Disease-Epidemiology-Insights-2023-150x58.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12122806\/Alzheimers-Disease-Epidemiology-Insights-2023-768x295.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12122806\/Alzheimers-Disease-Epidemiology-Insights-2023-1536x591.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12122806\/Alzheimers-Disease-Epidemiology-Insights-2023-2048x788.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<\/blockquote>\n\n\n\n<p>In <strong>June 2021, <\/strong>the US FDA granted accelerated approval to <a href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market\">Biogen and Eisai\u2019s ADUHELM (aducanumab)<\/a> for the treatment of people living with early Alzheimer\u2019s disease, including people with mild cognitive impairment due to Alzheimer\u2019s disease, making it the first available disease-modifying treatment to address<strong> Alzheimer\u2019s disease pathology<\/strong> by targeting amyloid plaques.<\/p>\n\n\n\n<p>The approval and launch of <strong>ADUHELM <\/strong>were mired in controversy, and the drug ultimately failed to make a significant impact in the market, with sales revenue remaining underwhelming. Biogen reported <strong>ADUHELM\u2019s<\/strong> revenue in the <strong>US <\/strong>to be<strong> $4.8 million in 2022<\/strong>. In <strong>2023,<\/strong> Aduhelm&#8217;s sales were not separately disclosed, as they were grouped under <strong><em>\u201cother product\u201d <\/em><\/strong>revenue. By discontinuing Aduhelm, Biogen can now shift its full focus to the continued commercialization of LEQEMBI (lecanemab), an anti-A\u03b2 monoclonal antibody developed in partnership with Eisai. With that, on<strong> January 31, 2024,<\/strong> Biogen announced that it would halt the development and commercialization of ADUHELM.\u00a0<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approval-of-leqembi-major-milestone-in-alzheimer-s-disease-treatment-space\"><span class=\"ez-toc-section\" id=\"FDA_Approval_of_Leqembi_Major_Milestone_in_Alzheimers_Disease_Treatment_Space\"><\/span><strong>FDA Approval of Leqembi: Major Milestone in Alzheimer\u2019s Disease Treatment Space<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In the most awaited regulatory decision of the summer, the FDA approved <strong>Eisai and Biogen\u2019s Leqembi<\/strong> <strong>(lecanemab)<\/strong> as the first anti-amyloid antibody\u2014and the first disease-altering drug\u2014for <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\">Alzheimer\u2019s disease treatment<\/a>. According to the FDA\u2019s announcement, the approval was obtained based on a confirmatory trial that demonstrated therapeutic benefit. According to the Clinical Dementia Rating-Sum of Boxes (CDR-SB) assessment, treatment with Leqembi reduced clinical decline by <strong>27%<\/strong> compared to placebo after 18 months in the <strong>Phase III Clarity-AD trial<\/strong>.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cToday marks a breakthrough in Alzheimer&#8217;s disease treatment, and we are proud to be at the forefront of ushering in a new era of advances for a disease that was previously thought to be incurable.\u201d \u201cWe would like to express our heartfelt gratitude to those who have worked tirelessly to find a cure for this intractable disease, without whom this progress would not have been possible,\u201d stated <\/em><strong><em>Christopher A. Viehbacher, President and Chief Executive Officer of Biogen.<\/em><\/strong><em> \u201cOur focus is now on the path forward, collaborating with Eisai to make LEQEMBI available to eligible patients as soon as possible.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Leqembi received fast approval from the FDA in January, but it was only available to a restricted number of patients since the Centres for Medicare and Medicaid Services (CMS) would only pay for the drug as part of a clinical trial. CMS affirmed in June that Leqembi will be covered \u201cin appropriate settings\u201d upon conventional approval, with the necessity of a patient registry to obtain real-world data on the utility of anti-amyloid antibodies in this indication.<\/p>\n\n\n\n<p>The result was largely anticipated after an advisory group overwhelmingly approved Leqembi last month. The FDA\u2019s Peripheral and Central Nervous System Drugs Advisory Committee approved 6-0 on June 9 to convert the accelerated approval to full clearance. The FDA is not required to follow the advice of its experts, but it frequently does\u2014as it did on July 6.<\/p>\n\n\n\n<p>While Leqembi\u2019s fast approval was welcomed as a success for a space that has seen few victories, experts were cautious in their enthusiasm, with Marwan Sabbagh of the Barrow Neurological Institute and a Clarity-AD investigator calling it a \u201cmodest victory.\u201d There are also unanswered uncertainties about the anti-amyloid antibody class\u2019s safety.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Developments_Since_the_Approval\"><\/span>Recent Developments Since the Approval<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In January 2025, BioArctic AB announced that the U.S. FDA has accepted Eisai&#8217;s Biologics License Application (BLA) for the LEQEMBI subcutaneous autoinjector (SC-AI) for weekly maintenance dosing. Later in the same month, Eisai Co., Ltd. and Biogen Inc. announced that the FDA had approved the Supplemental Biologics License Application (sBLA) for LEQEMBI intravenous (IV) maintenance dosing, administered once every four weeks. LEQEMBI is approved for the treatment of Alzheimer&#8217;s disease in patients with mild cognitive impairment (MCI) or mild dementia (early Alzheimer\u2019s disease) in the U.S. After an initial 18-month phase of dosing once every two weeks, patients may transition to the maintenance regimen of 10 mg\/kg every four weeks, or continue with the 10 mg\/kg every two weeks regimen.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Promising_Candidates_in_the_Pipeline_for_Alzheimers_Disease_Treatment\"><\/span><strong>Promising Candidates in the Pipeline for Alzheimer\u2019s Disease Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>As the prevalence of Alzheimer\u2019s disease continues to rise, there is a pressing need for effective treatments and interventions. Numerous companies are actively engaged in research and development efforts to combat Alzheimer&#8217;s disease, focusing on various approaches and therapeutic strategies.<\/p>\n\n\n\n<p>Expected launch of <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-pipeline-insight\">emerging Alzheimer\u2019s disease therapies<\/a>, such <strong>BioVie\u2019s NE3107, AB Science\u2019s masitinib (AB1010), Eli Lilly\u2019s remternetug (LY3372993), Cassava Sciences\u2019 simufilam (PTI-125), Novo Nordisk\u2019s semaglutide, Eisai\u2019s E2814, <\/strong>and others shall create a positive impact on the Alzheimer\u2019s disease treatment market.<\/p>\n\n\n\n<p><strong>NE3107 <\/strong>is being developed by <strong>BioVie\u2019s<\/strong>, is an oral, small molecule, blood-brain permeable, anti-inflammatory, insulin sensitizer that binds to extracellular signal-regulated kinase (ERK) and selectively inhibits inflammation. NE3107 is believed to inhibit extracellular ERK\/NFkB activation and TNF production stimulated by inflammatory mediators, such as lipopolysaccharides and Inhibits of NFkB activation and TNF production. BioVie is also developing the drug for treating Parkinson\u2019s disease, multiple myeloma, and prostate cancer. The company is currently conducting Phase III trials for the treatment of mild to moderate Alzheimer\u2019s disease.<\/p>\n\n\n\n<p><strong>Semaglutide (NN6535)<\/strong>, being developed by <strong>Novo Nordisk, i<\/strong>s a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the once-daily treatment of Alzheimer\u2019s disease. GLP\u20101 is an established neurotransmitter, and receptors for GLP\u20101 are expressed in numerous brain regions, including the striatum, nucleus accumbens, and hippocampus. Additionally, oral semaglutide is marketed as <strong>RYBELSUS (7 mg and 14 mg). <\/strong>It is approved as an adjunct to diet and exercise to improve glycaemic control in <a href=\"https:\/\/www.delveinsight.com\/report-store\/type-2-diabetes-market\">adults with type 2 diabetes<\/a> in the US, EU, and Japan. The drug is being investigated in two Phase III trials in subjects with early Alzheimer\u2019s disease. On <strong>October 24, 2024,<\/strong> a real-world study published in Alzheimer\u2019s and Dementia found that semaglutide is associated with a 40% to 70% reduction in the risk of Alzheimer&#8217;s diagnosis among patients with <strong>type 2 diabetes<\/strong>. This follows a July study based on health records from 100 million patients, which also linked the drug to a lower risk of dementia and other neurological disorders.&nbsp;<\/p>\n\n\n\n<p><strong>E2814<\/strong>, being developed by <strong>Eisai <\/strong>is a humanized, high-affinity monoclonal IgG1 antibody that recognizes the anti-microtubule binding region (MTBR) tau drug. The antibody binds to extracellular tau, prevents cell-to-cell propagation of pathogenic species, and mediates clearance by microglia. E2814 is designed to prevent the spreading of tau seeds within the brains of affected individuals. The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) has selected E2814 as the first investigational medicine among anti-tau drugs for their <strong>DIAN-TU tau study<\/strong>, and Phase Ib\/II study and Phase II\/III Tau NexGen study for dominantly inherited Alzheimer\u2019s disease are underway.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"645\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/12130406\/Emerging-Therapies-for-Alzheimers-disease-1-1024x645.png\" alt=\"Emerging-Therapies-for-Alzheimer's-disease\" class=\"wp-image-31019\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/12130406\/Emerging-Therapies-for-Alzheimers-disease-1-1024x645.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/12130406\/Emerging-Therapies-for-Alzheimers-disease-1-300x189.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/12130406\/Emerging-Therapies-for-Alzheimers-disease-1-150x95.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/12130406\/Emerging-Therapies-for-Alzheimers-disease-1-768x484.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/12130406\/Emerging-Therapies-for-Alzheimers-disease-1-1536x968.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/12130406\/Emerging-Therapies-for-Alzheimers-disease-1-2048x1290.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><strong>Remternetug (LY3372993),<\/strong> developed by <strong>Eli Lilly and Company<\/strong> is a monoclonal antibody being studied to treat early <strong>Alzheimer\u2019s disease.<\/strong> It is being investigated to administer through IV\/SC route and targets N3pG beta-amyloid (amyloid precursor protein). Remternetug is an antibody protein designed to target toxic amyloid plaques linked to the onset of Alzheimer\u2019s disease. In <strong><em>October 2024<\/em><\/strong>, the <strong>Phase III TRAILRUNNER-ALZ3 study<\/strong> was launched to assess Remternetug as a potential breakthrough in treating Alzheimer\u2019s disease. The trial plans to enroll <strong>1,200 participants<\/strong> with early-stage Alzheimer\u2019s, administering either subcutaneous injections of Remternetug or a placebo for 18 months, followed by a blinded observation phase.<\/p>\n\n\n\n<p>Other <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-pipeline-insight\">Alzheimer\u2019s disease drugs<\/a> like <strong>Piromelatine (Neurim Pharmaceuticals), Masupirdine (Suven Life Sciences), KarXT (Bristol Myers Squibb\/Karuna Therapeutics), T3D-959 (T3D Therapeutics), LX 1001 (Lexeo Therapeutics), AXS-05 (Axsome Therapeutics), ABvac40 (Araclon Biotech), Hydromethylthionine Mesylate (TauRx Therapeutics), TB006 (TrueBinding),<\/strong> and others are also being developed for Alzheimer\u2019s disease treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Promising_Future_Outlook_of_Alzheimers_Disease_Treatment\"><\/span><strong>Promising Future Outlook of Alzheimer\u2019s Disease Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The future outlook for Alzheimer\u2019s disease treatment appears promising, with ongoing research efforts and advancements in various areas. One significant focus of research is the development of more accurate and accessible diagnostic tools to identify Alzheimer\u2019s disease at an early stage. Advances in imaging techniques, such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/positron-emission-tomography-market\">positron emission tomography (PET) scans<\/a>, may allow for the detection of Alzheimer\u2019s-related brain changes before symptoms manifest.&nbsp;<\/p>\n\n\n\n<p>Researchers are exploring personalized approaches to Alzheimer\u2019s disease treatment by considering individual genetic factors, lifestyle choices, and other variables. This may lead to tailored treatment plans and interventions that are more effective in slowing down or preventing the progression of the disease.<\/p>\n\n\n\n<p>Moreover, technology may play a crucial role in the future <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-diagnostic-market\">management of Alzheimer\u2019s disease<\/a>. Wearable devices, smart homes, and digital health platforms could assist in monitoring patients, providing cognitive support, and detecting changes in behavior or health status. Artificial intelligence and machine learning algorithms may contribute to better prediction models and personalized treatment approaches.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1688970089855\"><strong class=\"schema-faq-question\"><strong>1. What is Alzheimer\u2019s disease?<\/strong><\/strong> <p class=\"schema-faq-answer\">Alzheimer\u2019s disease (AD) is a slowly progressive brain disease that manifests itself many years before symptoms appear. It is the leading cause of dementia, accounting for 60% to 80% of cases. The accumulation of the protein fragment beta-amyloid (plaques) outside neurons in the brain and twisted strands of the protein tau (tangles) inside neurons are the hallmark pathologies of Alzheimer\u2019s disease.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1688970224638\"><strong class=\"schema-faq-question\"><strong>2. What are the Alzheimer\u2019s disease symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">Alzheimer\u2019s disease is progressive, so the symptoms worsen over time. Memory loss is a key feature, and it is often one of the first Alzheimer\u2019s disease symptoms to appear. The other Alzheimer\u2019s disease symptoms include cognitive deficits, problems with recognition, problems with spatial awareness, and others.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1688970238989\"><strong class=\"schema-faq-question\"><strong>3. How is Alzheimer\u2019s disease diagnosed?<\/strong><\/strong> <p class=\"schema-faq-answer\">A thorough clinical evaluation, a detailed patient history, and various specialized tests are used to make an Alzheimer\u2019s disease diagnosis. Clinical Alzheimer\u2019s disease diagnosis, which is usually made during the early stages of the disease, lumbar puncture, and imaging studies are all methods of diagnosing Alzheimer\u2019s disease.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1688970336678\"><strong class=\"schema-faq-question\"><strong>4. What are the current Alzheimer\u2019s disease treatment options?<\/strong><\/strong> <p class=\"schema-faq-answer\">Alzheimer\u2019s disease treatment includes options that may alleviate symptoms and improve quality of life. To treat cognitive symptoms, the FDA has approved two types of medications to treat cognitive Alzheimer\u2019s disease symptoms: cholinesterase inhibitors (Aricept, Exelon, Razadyne) and memantine (Namenda). Other non-pharmacological therapies are also used to maintain or improve cognitive function, daily living ability, or overall quality of life.<\/p> <\/div> <\/div>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-1024x194.png\" alt=\"\" class=\"wp-image-31013\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Alzheimer\u2019s disease is the most common type of dementia, accounting for more than 60% of all cases, and is characterized by a gradual decline in cognitive and functional abilities. It represents a global health crisis that is increasing with the increasing geriatric population. It represents a global health crisis that is increasing with the increasing [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":31023,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[19079,7145,6642,72,13307,20372,21071],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-24025","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-aduhelm","tag-alzheimers-disease-market","tag-alzheimers-disease-pipeline","tag-alzheimers-disease","tag-alzheimers-disease-prevalence","tag-alzheimers-disease-treatment","tag-leqembi","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FDA Approval of Leqembi for Alzheimer\u2019s Disease Treatment<\/title>\n<meta name=\"description\" content=\"The future outlook for Alzheimer\u2019s disease treatment appears promising, with ongoing research efforts by the leading pharma companies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approval of Leqembi for Alzheimer\u2019s Disease Treatment\" \/>\n<meta property=\"og:description\" content=\"The future outlook for Alzheimer\u2019s disease treatment appears promising, with ongoing research efforts by the leading pharma companies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-12T07:44:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-12T08:10:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/12131545\/LEQEMBI-A-New-Hope-for-Alzheimers-Disease-Patients.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Approval of Leqembi for Alzheimer\u2019s Disease Treatment","description":"The future outlook for Alzheimer\u2019s disease treatment appears promising, with ongoing research efforts by the leading pharma companies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment","og_locale":"en_US","og_type":"article","og_title":"FDA Approval of Leqembi for Alzheimer\u2019s Disease Treatment","og_description":"The future outlook for Alzheimer\u2019s disease treatment appears promising, with ongoing research efforts by the leading pharma companies.","og_url":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-02-12T07:44:14+00:00","article_modified_time":"2025-02-12T08:10:16+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/12131545\/LEQEMBI-A-New-Hope-for-Alzheimers-Disease-Patients.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment","url":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment","name":"FDA Approval of Leqembi for Alzheimer\u2019s Disease Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/12131545\/LEQEMBI-A-New-Hope-for-Alzheimers-Disease-Patients.png","datePublished":"2025-02-12T07:44:14+00:00","dateModified":"2025-02-12T08:10:16+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"The future outlook for Alzheimer\u2019s disease treatment appears promising, with ongoing research efforts by the leading pharma companies.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment#faq-question-1688970089855"},{"@id":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment#faq-question-1688970224638"},{"@id":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment#faq-question-1688970238989"},{"@id":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment#faq-question-1688970336678"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/12131545\/LEQEMBI-A-New-Hope-for-Alzheimers-Disease-Patients.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/12131545\/LEQEMBI-A-New-Hope-for-Alzheimers-Disease-Patients.png","width":466,"height":284,"caption":"LEQEMBI A New Hope for Alzheimer\u2019s Disease Patients"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment#faq-question-1688970089855","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment#faq-question-1688970089855","name":"1. What is Alzheimer\u2019s disease?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Alzheimer\u2019s disease (AD) is a slowly progressive brain disease that manifests itself many years before symptoms appear. It is the leading cause of dementia, accounting for 60% to 80% of cases. The accumulation of the protein fragment beta-amyloid (plaques) outside neurons in the brain and twisted strands of the protein tau (tangles) inside neurons are the hallmark pathologies of Alzheimer\u2019s disease.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment#faq-question-1688970224638","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment#faq-question-1688970224638","name":"2. What are the Alzheimer\u2019s disease symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Alzheimer\u2019s disease is progressive, so the symptoms worsen over time. Memory loss is a key feature, and it is often one of the first Alzheimer\u2019s disease symptoms to appear. The other Alzheimer\u2019s disease symptoms include cognitive deficits, problems with recognition, problems with spatial awareness, and others.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment#faq-question-1688970238989","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment#faq-question-1688970238989","name":"3. How is Alzheimer\u2019s disease diagnosed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"A thorough clinical evaluation, a detailed patient history, and various specialized tests are used to make an Alzheimer\u2019s disease diagnosis. Clinical Alzheimer\u2019s disease diagnosis, which is usually made during the early stages of the disease, lumbar puncture, and imaging studies are all methods of diagnosing Alzheimer\u2019s disease.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment#faq-question-1688970336678","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/leqembi-for-alzheimers-disease-treatment#faq-question-1688970336678","name":"4. What are the current Alzheimer\u2019s disease treatment options?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Alzheimer\u2019s disease treatment includes options that may alleviate symptoms and improve quality of life. To treat cognitive symptoms, the FDA has approved two types of medications to treat cognitive Alzheimer\u2019s disease symptoms: cholinesterase inhibitors (Aricept, Exelon, Razadyne) and memantine (Namenda). Other non-pharmacological therapies are also used to maintain or improve cognitive function, daily living ability, or overall quality of life.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/12131545\/LEQEMBI-A-New-Hope-for-Alzheimers-Disease-Patients-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Aduhelm<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer&#039;s Disease Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer&#039;s disease pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s Disease Prevalence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s Disease Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Leqembi<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Aduhelm<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer&#039;s Disease Market<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer&#039;s disease pipeline<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer\u2019s Disease Prevalence<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer\u2019s Disease Treatment<\/span>","<span class=\"advgb-post-tax-term\">Leqembi<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Feb 12, 2025","modified":"Updated on Feb 12, 2025"},"absolute_dates_time":{"created":"Posted on Feb 12, 2025 1:14 pm","modified":"Updated on Feb 12, 2025 1:40 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/24025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=24025"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/24025\/revisions"}],"predecessor-version":[{"id":31030,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/24025\/revisions\/31030"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31023"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=24025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=24025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=24025"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=24025"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=24025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}